Serplulimab for Locally Advanced Cervical Cancer

Inclusion Criteria: 1. Voluntarily willing to participate in the clinical study, fully informed about the study, and signed the informed consent form (ICF); 2. Willing and able to comply with all study procedures; 3. Female aged 18-75 years; 4. ECOG performance status of 0 or 1; 5. PD-L1 status not restricted; 6. Histologically confirmed cervical squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma; 7. FIGO 2014 (International Federation of Gynecology and Obstetrics) stage IB2-IIB with positive lymph nodes, or stage III-IVA; 8. Patients must meet the following hematologic, renal, and hepatic function criteria: 9. Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L; Platelet count ≥ 100 × 10⁹/L; Total bilirubin, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) ≤ 1.5 × upper limit of normal (ULN); Serum creatinine ≤ upper limit of normal (ULN); No prior anti-tumor treatment; Expected survival \> 6 months; 10. Female subjects must have a negative serum pregnancy test within 14 days prior to study treatment, agree to use effective contraception during treatment and for 6 months after treatment, and breastfeeding is prohibited during the study. Exclusion Criteria: 1. Histologically confirmed small cell cervical cancer; 2. Recurrent cervical cancer or presence of distant metastases; 3. Prior anti-tumor treatment; 4. Current or history of another active, untreated malignancy within the past 5 years, except for adequately treated basal cell carcinoma of the skin or carcinoma in situ; 5. Any active or known autoimmune disease; 6. Active infection; 7. Requirement for systemic treatment with corticosteroids or other immunosuppressive agents within 14 days prior to randomization; 8. Arterial or venous thromboembolic events within 6 months prior to enrollment; 9. Uncontrolled clinically significant cardiac symptoms or disease; 10. Known allergy to the investigational drug or any of its excipients, or prior severe allergic reaction to other monoclonal antibodies; 11. Pregnant or breastfeeding women; 12. Neurological or psychiatric abnormalities affecting cognitive function; 13. Any other condition or situation that, in the investigator's judgment, would pose a serious risk to the subject's safety, potentially confound study results, or interfere with the subject's ability to complete the study.